Century Therapeutics, Inc. IPSC
1.19 USD -0.13 (-9.85%)
As ofNov 20, 2026, 12:05 PM EST
1.18 Day range 1.32
0.464 52-week range 3.04
- YTD
- +19.60%
- 1 year
- +142.36%
Analyst view
Consensus: buy
Buy
Price target (mean) 9.67 +712.3% upside
Now 1.19
- Target (low)
- 5.00
- Target (mean)
- 9.67
- Target (high)
- 12.00
Ratings (0m) 7 6 buy · 1 hold · 0 sell
- Strong buy2
- Buy4
- Hold1
- Sell0
- Strong sell0
Recommendation trend
- This month 7
- 1 month ago 7
Included in Essentials and up
Sign in to see Revenue and earnings forecast
Reported revenue and earnings per share by year, then what analysts expect next.
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.4375 | -0.47 – -0.41 | -0.4577 | +4.4% | 975.00K | +263.8% | 4 |
| Next quarter | -0.4425 | -0.46 – -0.42 | -0.45 | +1.7% | 633.33K | -25.9% | 4 |
| Current year | -1.59 | -1.66 – -1.45 | -2.03 | +21.6% | 3.29M | +47.2% | 5 |
| Next year | -1.83 | -1.98 – -1.63 | -1.59 | -15.0% | 3.77M | +14.5% | 5 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 7, 2024 | Chardan Capital | Maintained | Buy | Buy |
| Nov 6, 2024 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Aug 15, 2024 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Jun 17, 2024 | Piper Sandler | Maintained | Overweight | Overweight |
| Jun 4, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| May 10, 2024 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Apr 12, 2024 | Piper Sandler | Reiterated | Overweight | Overweight |
| Mar 15, 2024 | Canaccord Genuity | Maintained | Buy | Buy |
| Mar 15, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Dec 7, 2023 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Aug 28, 2023 | JP Morgan | Downgrade | Overweight | Neutral |
| Aug 10, 2023 | Piper Sandler | Maintained | Overweight | Overweight |
| Aug 10, 2023 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Aug 10, 2023 | EF Hutton | Reiterated | Buy | Buy |
| Aug 10, 2023 | Chardan Capital | Maintained | Buy | Buy |
| May 12, 2023 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Apr 17, 2023 | EF Hutton | Maintained | — | Buy |
| Apr 13, 2023 | HC Wainwright & Co. | Reiterated | — | Buy |
| Mar 22, 2023 | Chardan Capital | Reiterated | — | Buy |
| Mar 17, 2023 | HC Wainwright & Co. | Maintained | — | Buy |
| Mar 16, 2023 | EF Hutton | Reiterated | — | Buy |
| Feb 9, 2023 | HC Wainwright & Co. | Reiterated | — | Buy |
| Jan 6, 2023 | EF Hutton | Maintained | — | Buy |
| Jan 6, 2023 | SVB Leerink | Maintained | — | Outperform |
| Jan 6, 2023 | Piper Sandler | Maintained | — | Overweight |
| Jan 6, 2023 | HC Wainwright & Co. | Maintained | — | Buy |
| Jan 5, 2023 | EF Hutton | Initiated | — | Buy |
| Dec 27, 2022 | Chardan Capital | Initiated | — | Buy |
| Nov 14, 2022 | HC Wainwright & Co. | Maintained | — | Buy |
| Oct 31, 2022 | Guggenheim | Initiated | — | Buy |
Included in Plus and up
Sign in to see Analyst trend
Two years of the analyst rating mix and the average price target against the price.
